Skip to main content

Advertisement

Log in

Annual costs of rheumatoid arthritis in Turkey

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Objective of the present study is aimed to determine costs of rheumatoid arthritis (RA) based on reimbursement agencies perspective [Social Security Institution(SSI)] in Turkey. The international clinical guidelines for RA are followed for analysing the direct costs. Data were collected from hospital bills, social security institution price lists, and Ministry of Health drug price list. Direct costs of RA patients were estimated as €2,669.14 patient/year. Outpatient costs were found to be €240.40. Routine tests during the year were calculated as €98.85. Ten percent of patients are hospitalized per year, and 0.62% of these patients received arthroplasty and/or other interventions. The cost during hospital stay was €87.76. €2,238 was determined as being paid per year for medication alone (including anti-TNF) and €4 is spent on auxiliary materials annually. Our data show a remarkable economic impact of RA over society. We hope that the cost of RA studies will help package price practices for reimbursement agencies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Silman AJ, Pearson JE (2002) Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 4(Suppl 3):S265–S272. doi:10.1186/ar578

    Article  PubMed  Google Scholar 

  2. Kacar C, Gilgil E, Tuncer T, Bütün B, Urhan S, Arıkan V et al (2005) Prevalence of rheumatoid arthritis in Antalya, Turkey. Clin Rheumatol 24(3):212–214. doi:10.1007/s10067-004-1006-4

    Article  CAS  PubMed  Google Scholar 

  3. Turkish Republic Ministry of Health Refik Saydam Hygiene Center Presidency School of Public Health, “National Burden of Disease and Cost Effectiveness Study” 2005

  4. Fautrel B, Guillemin F (2002) Cost of illness studies in rheumatic diseases. Curr Opin Rheumatol 14:121–126. doi:10.1097/00002281-200203000-00008

    Article  PubMed  Google Scholar 

  5. Kobelt G, Eberhardt K, Geborek P (2004) TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 63:4–10. doi:10.1136/ard.2003.010629

    Article  CAS  PubMed  Google Scholar 

  6. Lambert CM (2001) Medical therapy for rheumatoid arthritis-value for money. Rheumatology 40:961–964. doi:10.1093/rheumatology/40.9.961

    Article  CAS  PubMed  Google Scholar 

  7. Cooper NC (2000) Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 39:28–33. doi:10.1093/rheumatology/39.1.28

    Article  CAS  PubMed  Google Scholar 

  8. Brennan A, Bansback N, Reynolds A, Conway P (2004) Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43:62–72. doi:10.1093/rheumatology/keg451

    Article  CAS  PubMed  Google Scholar 

  9. Péntek M, Kobelt G, Czirják L, Szekanecz Z, Poor G, Rojkovich B et al (2007) Costs of rheumatoid arthritis in Hungary. J Rheumatol 34:1437

    PubMed  Google Scholar 

  10. Liang MH, Larson M, Thompson M, Eaton H, McNamara E, Katz R et al (1984) Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 27:522–529. doi:10.1002/art.1780270507

    Article  CAS  PubMed  Google Scholar 

  11. American College of Rheumatology (2002) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 46(2):328–346. doi:10.1002/art.10148

    Article  Google Scholar 

  12. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66(1):34–45. doi:10.1136/ard.2005.044354

    Article  CAS  PubMed  Google Scholar 

  13. Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M et al (2003) Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 30:891–896

    PubMed  Google Scholar 

  14. Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V et al (2003) OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 30:886–890

    PubMed  Google Scholar 

  15. Bodur H, Ataman S, Akbulut L, Evcik D, Kavuncu V, Kaya T et al (2008) Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 27:1119–1125. doi:10.1007/s10067-008-0877-1

    Article  CAS  PubMed  Google Scholar 

  16. T.C. Sağlık Bakanlığı İlaç Eczacılık Genel Müdürlüğü Temel İlaç Fiyat listesi

  17. T.C. Sosyal Güvenlik Kurumu Sağlık Uygulama Tebliği

  18. Cowley P, Bodabilla L, Musgrove P, Saxenian H (1994) Content and Financing of an essential national package of health services, global assessments in the health sector, World Health Organization, pp 171–181

  19. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH (1986) Multicenter study of annual health service utilization and cost in rheumatoid arthritis. Arthritis Rheum 29:488–493. doi:10.1002/art.1780290405

    Article  CAS  PubMed  Google Scholar 

  20. Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M et al (1997) Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 24:1051–1060

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Simten Malhan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malhan, S., Akbulut, L.A., Bodur, H. et al. Annual costs of rheumatoid arthritis in Turkey. Rheumatol Int 30, 637–641 (2010). https://doi.org/10.1007/s00296-009-1040-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-009-1040-2

Keywords

Navigation